Oral Administration of Microencapsulated B. Longum BAA-999 and Lycopene Modulates IGF-1/IGF-1R/IGFBP3 Protein Expressions in a Colorectal Murine Model

• Published in: International journal of molecular sciences Vol. 20; no. 17; p. 4275
• Main Authors: Valadez-Bustos, Nancy, Escamilla-Silva, Eleazar M, García-Vázquez, Francisco J, Gallegos-Corona, Marco A, Amaya-Llano, Silvia L, Ramos-Gómez, Minerva
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 31.08.2019; MDPI
• Subjects: Administration, Oral; Animal models; Animals; Anticarcinogenic Agents - administration & dosage; Anticarcinogenic Agents - therapeutic use; Apoptosis; Azoxymethane; B. longum microencapsulated; Bacteria; Bifidobacterium longum - physiology; Bile acids; Cancer; Carbohydrates; Carcinogenesis; Carcinogens; Cell cycle; Cell differentiation; Cell growth; Cell proliferation; Colon; Colonization; Colorectal cancer; Colorectal Neoplasms - pathology; Colorectal Neoplasms - therapy; Dextran; Dextran sulfate; Disease Models, Animal; Drying; Epithelial cells; Fatalities; Feces; Fermentation; gastrointestinal bacterial distribution; Gastrointestinal system; Gastrointestinal tract; IGF-1/IGF-1R/IGFBPs system; Insulin; Insulin-Like Growth Factor Binding Protein 3 - analysis; Insulin-like growth factor I; Insulin-Like Growth Factor I - analysis; Insulin-like growth factor-binding protein 3; Intestinal microflora; Intestine; Lycopene; Lycopene - administration & dosage; Lycopene - therapeutic use; Male; Mice; Mice, Inbred ICR; Mucus; Prebiotics; Probiotics; Probiotics - administration & dosage; Probiotics - therapeutic use; Receptor, IGF Type 1 - analysis; Spray drying; colorectal cancer; lycopene; gastrointestinal bacterial distribution; B. longum microencapsulated; IGF-1/IGF-1R/IGFBPs system
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms20174275

The Insulin-like growth factor-I/Insulin-like growth factor-I receptor (IGF-1/IGF-1R) system is a major determinant in colorectal cancer (CRC) pathogenesis. Probiotics ( , BF) and lycopene (LYC) have been individually researched for their beneficial effects in the prevention of CRC. However, the effect of a combined treatment of microencapsulated BF and LYC on IGF-1/IGF-1R/IGFBPs (Insulin-like growth factor-binding proteins) expression in an azoxymethane (AOM)-dextran sulfate sodium (DSS)-induced CRC model have not been demonstrated. BF was microencapsulated by the spray drying technique, with high viability, and daily gavaged with LYC for 16 weeks to CD-1 mice in an AOM-DSS model. The results indicated that BF- and BF + LYC-treated groups had significantly lower inflammation grade, tumor incidence (13-38%) and adenocarcinoma (13-14%) incidence compared to the AOM + DSS group (80%), whereas LYC treatment only protected against inflammation grade and incidence. Caecal, colonic and fecal pH and β-glucuronidase (β-GA) values were significantly normalized by BF and LYC. Similarly, BF and BF + LYC treatments significantly reduced both the positive rate and expression grade of IGF-1 and IGF-1R proteins and normalized Insulin-like growth factor-binding protein-3 (IGFBP3) expression. Based on intestinal parameters related to the specific colon carcinogenesis in an AOM-DSS-induced model, LYC and microencapsulated BF supplementation resulted in a significant chemopreventive potential through the modulation of IGF-1/IGF-1R system.